AbbVie announced positive top-line results from its Phase III clinical trial of upadacitinib (ABT-494) in moderate-to-severe rheumatoid arthritis patients.
Regeneron Pharmaceuticals Inc.’s second-quarter 2017 profit handsomely beat estimates on strong demand for its flagship Eylea drug.
The benefits of Johnson & Johnson’s experimental rheumatoid arthritis drug sirukumab do not outweigh the risks, an advisory panel to the U.S. FDA concluded.
Pfizer’s second-quarter 2017 revenue missed Wall Street estimates, hurt by falling demand for its blockbuster pneumonia vaccine Prevnar as well as older drugs.
There were more deaths in patients taking J&J’s experimental rheumatoid arthritis drug sirukumab than among those taking a placebo, FDA staff reviewers said.
Eli Lilly reported an increase of 8 percent in second-quarter 2017 revenue, but the real shake-up is what the company plans to do with its pipeline.
Japan’s Ministry of Health, Labor and Welfare granted marketing approval for Olumiant (baricitinib) 2-mg and 4-mg tablets for the treatment of rheumatoid arthritis.